Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man

What Was Tested

The paper reports a study of Glucagon and Peptide YY, published as a randomized controlled trial.

The aim of the present study was to examine the effects of GLP-1 might be similar.

The aim of the present study was to examine the effects of GLP-1 and PYY on the vagally induced gastric acid secretion in man.

Why It Was Studied

Glucagon-like peptide (GLP-1) 7-36 amide and peptide YY (PYY) from the L-cell of the ileal mucosa are potent inhibitors of gastric acid secretion in man.

It is not clear, however, by which mechanism(s) they inhibit acid secretion.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

A modified sham feeding technique, chew and spit, was used.

What Was Measured

The subject headings attached to it are Depression, Chemical, Gastric Acid, Gastrins, Glucagon, Glucagon-Like Peptide 1, Glucagon-Like Peptides and Ileum.

What This Means in Plain Language

The paper is a randomized study of Glucagon and Peptide YY.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1994 (Scandinavian journal of gastroenterology), a journal based in England.

More context: the Glucagon compound page and the Peptide YY compound page, all human trials.